
Opinion|Videos|January 17, 2025
Diving Deep Into the CEPHEUS Trial: Subcutaneous Dara-VRd vs VRd in Transplant-Ineligible or Transplant-Deferred NDMM
Panelists discuss how the CEPHEUS trial demonstrates the comparative efficacy and safety of subcutaneous daratumumab combined with VRd vs VRd alone in patients with transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma, highlighting key outcomes and clinical implications.
Episodes in this series






































